18 Jul 2017 08:47
Director Dealings / Market Share Sale and Purchase
Oxford, UK - 18 July 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 14 July 2017 James Miskin, Chief Technical Officer, exercised 930,000 options at 1p and sold all of the resulting shares at 8.1p. Following this transaction he holds 7,104,836 options and no shares in the company.
The issued share capital of the Company is 3,094,999,848 1p ordinary shares.
-Ends-
For further information, please contact: |
|
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer |
Tel: +44 (0)1865 783 000 |
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton |
Tel: +44 (0)20 3709 5700 |
Notes for editors
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.
Oxford Biomedica (OXB)